Keros Therapeutics, Inc. (KROS) Deferred Tax Assets, Valuation Allowance USD 2019 - 2023

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Keros Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from 2019 to 2023.
  • Keros Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $99.4M, a 63.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly Data (USD)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $99.4M +$38.7M +63.9% Dec 31, 2023 10-K 2024-02-28
Q4 2022 $60.7M +$25.2M +71.1% Dec 31, 2022 10-K 2024-02-28
Q4 2021 $35.4M +$17.5M +97.6% Dec 31, 2021 10-K 2023-03-03
Q4 2020 $17.9M +$12M +203% Dec 31, 2020 10-K 2022-03-09
Q4 2019 $5.92M Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.